Vaxcyte says Phase 3 OPUS-1 trial of VAX-31 meets primary endpoints in adults versus Prevnar 20, Capvaxive

By Public Technologies
  • Vaxcyte reported positive topline results from OPUS-1, a pivotal adult Phase 3 trial of its VAX-31 pneumococcal vaccine.
  • The study met its primary goals across age groups, supporting the program’s case for regulatory filing in the US.
  • Results indicated immune responses broadly comparable to leading adult pneumococcal vaccines, with added coverage for strains not included in them.
  • Safety and tolerability were broadly similar to existing comparator vaccines in the trial.
  • Additional Phase 3 readouts are expected in the first half of 2027, ahead of a planned BLA submission in the first half of 2028.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxcyte Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610050600PRIMZONEFULLFEED9839330) on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.